Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $3.35 Analyst target: $11.60 Upside: 246.27%
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back diseases. The company is headquartered in Boston, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.